- Home
- MXE vs IMA Comparison
MXE vs IMA Comparison
Compare MXE & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MXE | IMA |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 66.3M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | MXE | IMA |
|---|---|---|
| Price | $13.15 | $5.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 2.1K | ★ 37.6K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.03 | $3.94 |
| 52 Week High | $14.30 | $17.50 |
Technical Indicators
Market Signals| Indicator | MXE | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 48.02 |
| Support Level | $13.07 | $5.23 |
| Resistance Level | $14.17 | $6.12 |
| Average True Range (ATR) | 0.35 | 0.34 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 38.13 | 42.31 |
Price Performance
Historical ComparisonAbout MXE Mexico Equity and Income Fund Inc. (The)
Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.